#United States #New York #Gross Law Firm #MoonLake #MLTX

Legal Update for MoonLake Immunotherapeutics Shareholders

The Gross Law Firm Notification
On November 6, 2025, The Gross Law Firm issued a critical notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX), highlighting the onset of a class action lawsuit concerning the company's potential misrepresentations. Shareholders are strongly encouraged to reach out to the firm to discuss participation as a lead plaintiff, with the acknowledgment that there is no requirement to assume that role to partake in any recoveries.

Class Period Overview
The class period relevant to this lawsuit spans from March 10, 2024, to September 29, 2025. The claims put forth allege that the defendants issued statements that were misleading and failed to timely disclose essential details detrimental to the company's true standing. It is particularly noted that key issues are related to the drug candidates of the company, specifically SLK and BIMZELX. In short, the lawsuit asserts that these drug candidates operate on the same molecular targets (the inflammatory cytokines IL-17A and IL-17F), with claims suggesting that SLK's unique Nanobody structure may not carry the clinical advantages initially professed.

Allegations Detailed
Upon examining the filed complaints, several allegations have surfaced:
1. Misleading Statements: The complaint alleges significant inaccuracies around the performance and capabilities of SLK compared to standard monoclonal antibodies like BIMZELX.
2. Clinical Efficacy Concerns: The distinct Nanobody structure claimed to enhance tissue penetration may not translate into improved clinical outcomes, raising red flags over the clinical efficacy of the drug.
3. Groundless Optimism: Based on these allegations, it is suggested that the optimism expressed by the defendants regarding SLK's effectiveness isn't substantiated, indicating a lack of reasonable grounds for their statements about the drug's superiority.

Critical Deadline for Shareholders
Shareholders affected by the aforementioned circumstances are urged not to delay in registering for this class action. The deadline to seek lead plaintiff status is December 15, 2025. This timeline emphasizes the urgency for shareholders who might have been misled during the class period to come forward and register their details. By doing so, they will benefit from portfolio monitoring software that will keep them updated on the case's progress, assisting them in any steps they might consider taking.

Why Choose The Gross Law Firm?
The Gross Law Firm is recognized nationwide for its commitment to advocating for investors' rights, particularly those who have suffered losses due to fraudulent practices and deceit. The firm emphasizes the importance of responsible corporate behavior and is dedicated to pursuing recoveries on behalf of investors who have been misled by false or misleading statements. The absence of charges for participation affirms a willingness to advocate strongly for affected shareholders.

Contact Information
For shareholders interested in more information or who wish to register, they can reach out directly:

• - Email: [email protected]
• - Phone: (646) 453-8903
• - Address: The Gross Law Firm, 15 West 38th Street, 12th Floor, New York, NY, 10018.

This class action lawsuit stands as a significant opportunity for shareholders of MLTX to seek accountability and reparation for any damages sustained due to alleged actions by the company.

Stay informed and proactive, as participating in such cases could yield benefits from potential settlements or recoveries.

• ---

This article serves as a summary of the current situation and should not be construed as legal advice.